T cell receptor (TCR) gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naive and memory T cells without prior stimulation of endogenous TCR

Human Gene Therapy

Volumn 20, Issue 12, 2009, Pages 1576-1588

  Circosta, Paola ^a,b   Granziero, Luisa ^a   Follenzi, Antonia ^c   Vigna, Elisa ^a   Stella, Stefania ^a   Vallario, Antonella ^c   Elia, Angela Rita ^a   Gammaitoni, Loretta ^a   Vitaggio, Katiuscia ^a   Orso, Francesca ^b   Geuna, Massimo ^d   Sangiolo, Dario ^a   Todorovic, Maja ^a   Giachino, Claudia ^b   Cignetti, Alessandro ^a  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^d MAURIZIANO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CYTOKINE; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 7; LENTIVIRUS VECTOR; MELAN A; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ALPHA CHAIN; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; BETA CHAIN; BINDING AFFINITY; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CELL STIMULATION; CONTROLLED STUDY; EMBRYO; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; LYMPHOCYTE DIFFERENTIATION; MELANOMA CELL; MEMORY T LYMPHOCYTE; MOLECULAR RECOGNITION; PERIPHERAL BLOOD MONONUCLEAR CELL; T LYMPHOCYTE SUBPOPULATION; VITILIGO;

ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOLOGIC MEMORY; LENTIVIRUS; MELANOMA; NEOPLASM PROTEINS; RECEPTORS, ANTIGEN, T-CELL; TRANSDUCTION, GENETIC; VITILIGO;

EID: 70349929446     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2009.117     Document Type: Article

References (42)

1. + T cells in vitro. Blood 102, 2541-2546.
2. Amendola, M., Venneri, M.A., Biffi, A., Vigna, E., and Naldini, L. (2005). Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. Nat. Bio-technol. 23, 108-116.
3. Boyman, O., Purton, J.F., Surh, C.D., and Sprent, J. (2007). Cyto-kines and T-cell homeostasis. Curr. Opin. Immunol. 19, 320-326.
4. Cavalieri, S., Cazzaniga, S., Geuna, M., Magnani, Z., Bordignon, C., Naldini, L., and Bonini, C. (2003). Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. Blood 102, 497-505.
5. Cignetti, A., Vallario, A., Follenzi, A., Circosta, P., Capaldi, A., Gottardi, D., Naldini, L., and Caligaris-Cappio, F. (2005). Lentiviral transduction of primary myeloma cells with CD80 and CD154 generates antimyeloma effector T cells. Hum. Gene Ther. 16, 445-456.
6. Cohen, C.J., Zhao, Y., Zheng, Z., Rosenberg, S.A., and Morgan, R.A. (2006). Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR=CD3 stability. Cancer Res. 66, 8878-8886.
7. Cohen, C.J., Li, Y.F., El Gamil, M., Robbins, P.F., Rosenberg, S.A., and Morgan, R.A. (2007). Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 67, 3898-3903.
8. Gattinoni, L., Powell, D.J., Jr., Rosenberg, S.A., and Restifo, N.P. (2006). Adoptive immunotherapy for cancer: Building on success. Nat. Rev. Immunol. 6, 383-393.
9. Hart, D.P., Xue, S.A., Thomas, S., Cesco-Gaspere, M., Tranter, A., Willcox, B., Lee, S.P., Steven, N., Morris, E.C., and Stauss, H.J. (2008). Retroviral transfer of a dominant TCR prevents surface expression of a large proportion of the endogenous TCR repertoire in human T cells. Gene Ther. 15, 625-631.
10. Heemskerk, M.H., Hagedoorn, R.S., van der Hoorn, M.A., van der Veken, L.T., Hoogeboom, M., Kester, M.G., Willemze, R., and Falkenburg, J.H. (2007). Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood 109, 235-243.
11. Heemskerk, M.H., Griffioen, M., and Falkenburg, J.H. (2008). T-cell receptor gene transfer for treatment of leukemia. Cy-totherapy 10, 108-115.
12. + T cells for adoptive immunotherapy. Blood 111, 5326-5333.
13. Kay, M.A., Glorioso, J.C., and Naldini, L. (2001). Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics. Nat. Med. 7, 33-40.
14. Kuball, J., Dossett, M.L., Wolfl, M., Ho, W.Y., Voss, R.H., Fowler, C., and Greenberg, P.D. (2007). Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 109, 2331-2338.
15. Mantovani, S., Palermo, B., Garbelli, S., Campanelli, R., Robus-telli Della, C.G., Gennari, R., Benvenuto, F., Lantelme, E., and Giachino, C. (2002). Dominant TCR-a requirements for a self antigen recognition in humans. J. Immunol. 169, 6253-6260.
16. Marktel, S., Magnani, Z., Ciceri, F., Cazzaniga, S., Riddell, S.R., Traversari, C., Bordignon, C., and Bonini, C. (2003). Im-munologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. Blood 101, 1290-1298.
17. Montini, E., Cesana, D., Schmidt, M., Sanvito, F., Ponzoni, M., Bartholomae, C., Sergi, S.L., Benedicenti, F., Ambrosi, A., Di Serio, C., Doglioni, C., von Kalle, C., and Naldini, L. (2006). Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotechnol. 24, 687-696.
18. Morgan, R.A., Dudley, M.E., Wunderlich, J.R., Hughes, M.S., Yang, J.C., Sherry, R.M., Royal, R.E., Topalian, S.L., Kammula, U.S., Restifo, N.P., Zheng, Z., Nahvi, A., de Vries, C.R., Rogers-Freezer, L.J., Mavroukakis, S.A., and Rosenberg, S.A. (2006). Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126-129.
19. Oyarbide-Valencia, K., van den Boorn, J.G., Denman, C.J., Li, M., Carlson, J.M., Hernandez, C., Nishimura, M.I., Das, P.K., Luiten, R.M., and Le Poole, I.C. (2006). Therapeutic implications of autoimmune vitiligo T cells. Autoimmun. Rev. 5, 486-492.
20. Palermo, B., Campanelli, R., Mantovani, S., Lantelme, E., Man-ganoni, A.M., Carella, G., Da Prada, G., della Cuna, G.R., Romagne, F., Gauthier, L., Necker, A., and Giachino, C. (2001). Diverse expansion potential and heterogeneous avidity in tumor-associated antigen-specific T lymphocytes from primary melanoma patients. Eur. J. Immunol. 31, 412-420.
21. Palermo, B., Campanelli, R., Garbelli, S., Mantovani, S., Robus-telli Della, C.G., Necker, A., Manganoni, A.M., Carella, G., Rivoltini, L., Lantelme, E., and Giachino, C. (2002). Cytotoxic T-lymphocyte responses in melanoma through in vitro stimulation with the Melan-A peptide analogue A27L: A qualitative analysis. Melanoma Res. 12, 491-498.
22. Palermo, B., Garbelli, S., Mantovani, S., and Giachino, C. (2005a). Transfer of efficient anti-melanocyte T cells from vitiligo donors to melanoma patients as a novel immunotherapeutical strategy. J. Autoimmune Dis. 2, 7.
23. Palermo, B., Garbelli, S., Mantovani, S., Scoccia, E., Da Prada, G.A., Bernabei, P., Avanzini, M.A., Brazzelli, V., Borroni, G., and Giachino, C. (2005b). Qualitative difference between the cytotoxic T lymphocyte responses to melanocyte antigens in melanoma and vitiligo. Eur. J. Immunol. 35, 3153-3162.
24. Pfeifer, A., Ikawa, M., Dayn, Y., and Verma, I.M. (2002). Transgenesis by lentiviral vectors: Lack of gene silencing in mammalian embryonic stem cells and preimplantation embryos. Proc. Natl. Acad. Sci. U.S.A. 99, 2140-2145.
25. Rosenberg, S.A., Restifo, N.P., Yang, J.C., Morgan, R.A., and Dudley, M.E. (2008). Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8, 299-308.
26. Sauce, D., Bodinier, M., Garin, M., Petracca, B., Tonnelier, N., Duperrier, A., Melo, J.V., Apperley, J.F., Ferrand, C., Herve, P., Lang, F., Tiberghien, P., and Robinet, E. (2002). Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms. Blood 99, 1165-1173.
27. Schumacher, T.N.M. (2002). T-cell-receptor gene therapy. Nat. Rev. Immunol. 2, 512-519.
28. Sebestyen, Z., Schooten, E., Sals, T., Zaldivar, I., San Jose, E., Alarcon, B., Bobisse, S., Rosato, A., Szollosi, J., Gratama, J.W., Willemsen, R.A., and Debets, R. (2008). Human TCR that incorporate CD3z induce highly preferred pairing between TCRa and b chains following gene transfer. J. Immunol. 180, 7736-7746.
29. Sommermeyer, D., Neudorfer, J., Weinhold, M., Leisegang, M., Engels, B., Noessner, E., Heemskerk, M.H., Charo, J., Schendel, D.J., Blankenstein, T., Bernhard, H., and Uckert, W. (2006). Designer T cells by T cell receptor replacement. Eur. J. Immunol. 36, 3052-3059.
30. Thomas, S., Xue, S.A., Cesco-Gaspere, M., San Jose, E., Hart, D.P., Wong, V., Debets, R., Alarcon, B., Morris, E., and Stauss, H.J. (2007a). Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells. J. Immunol. 179, 5803-5810.
31. Thomas, S., Hart, D.P., Xue, S.A., Cesco-Gaspere, M., and Stauss, H.J. (2007b). T-cell receptor gene therapy for cancer: The progress to date and future objectives. Expert Opin. Biol. Ther. 7, 1207-1218.
32. Tiberghien, P., Cahn, J.Y., Brion, A., Deconinck, E., Racadot, E., Herve, P., Milpied, N., Lioure, B., Gluckman, E., Bordigoni, P., Jacob, W., Chiang, Y., Marcus, S., Reynolds, C., and Longo, D. (1997). Use of donor T-lymphocytes expressing herpes-simplex thymidine kinase in allogeneic bone marrow transplantation: A phase I-II study. Hum. Gene Ther. 8, 615-624.
33. Tsuji, T., Yasukawa, M., Matsuzaki, J., Ohkuri, T., Chamoto, K., Wakita, D., Azuma, T., Niiya, H., Miyoshi, H., Kuzushima, K., Oka, Y., Sugiyama, H., Ikeda, H., and Nishimura, T. (2005). Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes. Blood 106, 470-476.
34. Valmori, D., Fonteneau, J.F., Lizana, C.M., Gervois, N., Lienard, D., Rimoldi, D., Jongeneel, V., Jotereau, F., Cerottini, J.C., and Romero, P. (1998). Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A=MART-1 immuno-dominant peptide analogues. J. Immunol. 160, 1750-1758.
35. Viola, A., and Lanzavecchia, A. (1996). T cell activation determined by T cell receptor number and tunable thresholds. Science 273, 104-106.
36. Volpe, G., Cignetti, A., Panuzzo, C., Kuka, M., Vitaggio, K., Brancaccio, M., Perrone, G., Rinaldi, M., Prato, G., Fava, M., Geuna, M., Pautasso, M., Casnici, C., Signori, E., Tonon, G., Tarone, G., Marelli, O., Fazio, V.M., and Saglio, G. (2007). Alternative BCR=ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for im-munotherapy approaches. Cancer Res. 67, 5300-5307.
37. Voss, R.H., Kuball, J., Engel, R., Guillaume, P., Romero, P., Huber, C., and Theobald, M. (2006). Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression. Immunol. Res. 34, 67-87.
38. Waldmann, T.A. (2006). The biology of interleukin-2 and interleukin-15: Implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 6, 595-601.
39. Weijtens, M., van Spronsen, A., Hagenbeek, A., Braakman, E., and Martens, A. (2002). Reduced graft-versus-host disease-inducing capacity of T cells after activation, culturing, and magnetic cell sorting selection in an allogeneic bone marrow transplantation model in rats. Hum. Gene Ther. 13, 187-198.
40. Yang, S., Cohen, C.J., Peng, P.D., Zhao, Y., Cassard, L., Yu, Z., Zheng, Z., Jones, S., Restifo, N.P., Rosenberg, S.A., and Morgan, R.A. (2008a). Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Ther. 15, 1411-1423.
41. Yang, S., Rosenberg, S.A., and Morgan, R.A. (2008b). Clinical-scale lentiviral vector transduction of PBL for TCR gene therapy and potential for expression in less-differentiated cells. J. Immunother. 31, 830-839.
42. Zhou, J., Shen, X., Huang, J., Hodes, R.J., Rosenberg, S.A., and Robbins, P.F. (2005). Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J. Immunol. 175, 7046-7052.